Cognito Therapeutics raises $35M Series B extension

Jan 30, 2024•almost 2 years ago

Amount Raised

$35 Million

CambridgeHealth CareManufacturing

Investors

WsgrStarbloomIag CapitalAlzheimer’s Drug Discovery FoundationMorningsideFounders X

Description

Cognito Therapeutics raised a $35 million Series B extension round, bringing the total round to $108 million and its total funding to $128 million. The funding will be used to support the HOPE study for the treatment of Alzheimer’s, as well as the continued expansion and protection of its IP position in gamma frequency therapy. It will also be used to support its Ph2 studies in Multiple Sclerosis and Parkinson’s Disease.

Company Information

Company

Cognito Therapeutics

Location

55 CAMBRIDGE PKWY

Cambridge, Massachusetts, United States

About

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends